Amniolife Corporation

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales. The COO, has built 12 tissue manufacturing facilities and was instrumental in the development of the BioCleanse® process owned by Regeneration Technologies (NASDAQ:RTIX). The Company's CTO, Previously served as Medical Director for Novartis Pharmaceuticals (NYSE:NVS), and launched Apligraft, a wound care biologic with over $125M in sales in 2011 Edit